Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Thursday, July 30, 2026

Snapshot: Jul 30, 2026 · 6:00 PM 100 stocks analyzed

Up Day

Thu, Jul 30, 2026 Divergent Extreme

Extreme single-stock volatility overwhelmed a choppy, divergent market as tech and healthcare stocks whipsawed sharply in opposite directions, with the Nasdaq down 1.2% despite …

55% Extreme dispersion with 50 stocks surging over 35% on average and 50 crashing 24%+ on average—including tech gainers like PN (+83%, Cesun acquisition), SNDK (+32%, chip rally), and FORM (+26%, AI demand) clashing against healthcare collapses like KPTI (−68%, Phase 3 miss), CAPR (−36%, FDA rejection), and MYGN (−33%, revenue miss)—made this a day of violent stock-pickers' bidding rather than a coherent macro move.
30% The S&P 500 eked out +0.40% and small caps (Russell 2000) +0.20% while the Nasdaq 100 tanked −1.22%, marking a stark value rotation out of mega-cap tech; VIX dropped 8% on the up day, signaling complacency despite the carnage in individual names, suggesting institutional capital rotated rather than fled.
15% Technology dominated gainers (42% of top 50) on chip-stock momentum and AI infrastructure enthusiasm, while Healthcare hemorrhaged (39% of top 50 losers) from a cascade of missed trials, earnings disappointments, and dilutive offerings, with persistent losers YYAI (4 days), ZIVO (3 days), and IAUX.WT (3 days) grinding lower.

Technology drove 42% of gainers 5 names returned after long absences YYAI · 4-day losers streak ZIVO · 3-day losers streak TONT.WT — first appearance CMCO — first appearance

Market Regime

Thu, Jul 30, 2026 Neutral conf: medium macro · prototype

Neutral −100 … +100 · + tailwind / − headwind

VIX17.1 p50 Drawdown-2.3% Held1d · nascent SinceJul 30

Top drivers: S&P drawdown (60d) ▲ VIX 5d momentum ▲ Small-cap leadership ▼

processId: history-market-regime

Market Indexes

Thu, Jul 30, 2026 13

S&P 500

7,437.63

+29.33

+0.40%

Dow Jones

52,208.06

+496.41

+0.96%

NASDAQ Composite

25,122.18

−15.51

-0.06%

NASDAQ 100

28,106.35

−348.46

-1.22%

DJ US Total Market

73,683.62

+267.57

+0.36%

Russell 1000

4,051.49

+18.04

+0.45%

S&P MidCap 400

3,764.47

−4.75

-0.13%

Russell 2000

2,946.10

+5.94

+0.20%

Russell 2500

1,255.98

+12.61

+1.01%

Russell 3000

4,232.18

+18.40

+0.44%

Nasdaq Financial-100

7,440.37

+28.28

+0.38%

NIFTY 50

24,317.15

+549.70

+2.31%

VIX

17.09

−1.49

-8.02%

Biggest Gainers

Thu, Jul 30, 2026 50

BRUNW

Boost Run Inc. Warrant

$8.50+$4.19

+97.2%

Skycorp Solar Group Limited Ordinary SharesEnergy

$23.64+$9.54

+83.1%

NASDAQ · Mkt cap $5.4 M

PN Smart Energy announced completion of its acquisition of Nanjing Cesun Power on July 30, advancing its strategy as an independent power producer, which likely triggered the 83% single-day surge as investors responded positively to the strategic milestone.

The headline directly references PN Smart Energy completing an acquisition of Nanjing Cesun Power, framed as advancing the company's transition toward becoming an independent power producer. This is a substantive corporate action—a completed M&A deal—that represents material progress on the company's stated strategic direction. An 83% one-day gain following an acquisition announcement is consistent with investor enthusiasm for transformational growth or a strategic pivot that had been anticipated or signaled previously. The timing of the news release on the same day as the price jump (July 30) supports causation. However, the excerpt provided does not contain details on deal size, terms, financial impact, or how this acquisition was previously positioned to the market, so we cannot quantify the specific catalysts within the transaction itself.

AMZE

Fresh Vine Wine, Inc.Technology

$0.20+$0.13

+74.9%

NYSE · Mkt cap $1.5 M

No news headlines were found in the last 48 hours to explain Fresh Vine Wine's 75% intraday surge, making the catalyst unclear and likely rooted in technical, rumor-driven, or delayed announcement activity typical of low-priced stocks.

Fresh Vine Wine traded up sharply to rank among the day's top three gainers, yet zero headlines appeared in the Yahoo Finance RSS feed within the relevant window. This absence of reported news is notable. For micro-cap stocks trading below $1, price moves of this magnitude often reflect thin liquidity, short-covering, retail momentum, or unconfirmed social media chatter rather than fundamental corporate events. Alternatively, a material announcement may have been issued but not yet picked up by the major news feed, or the move could be a delayed reaction to older events. Without access to the company's investor relations channel or real-time social platforms, the specific trigger remains unknown.

DFNS

Defense Industries International IncIndustrials

$84.96+$32.21

+61.1%

NYSE · Mkt cap $27 M

No news headlines were found in the last 48 hours, so the 61% gain cannot be attributed to a confirmed recent announcement. The move likely reflects either a delayed market reaction to an earlier event, a technical or sentiment-driven rally, or untracked news.

The absence of any Yahoo Finance headlines in the last 48 hours makes it impossible to pinpoint a specific catalyst for DFNS's 61% gain. For a defense contractor, typical catalysts include major contract awards, earnings beats, guidance raises, or geopolitical developments affecting defense spending. Without headline evidence, the move could reflect several scenarios: a delayed market digestion of news from before the 48-hour window, short-covering or momentum-driven technical buying in a small-cap or thinly-traded security, or breaking news that has not yet been indexed by the RSS feed. The stock's 4 ranking among gainers suggests broad sector interest, but this alone does not establish cause.

MTNB

Matinas BioPharma Holdings IncHealthcare

$0.32+$0.15

+52.7%

NYSE · Mkt cap $1.3 M

No news about MTNB was provided in the headlines; the 52.67% gain appears unrelated to the reported GH Power clean energy story, suggesting an internal catalyst such as clinical trial results, financing news, or technical/short-squeeze activity.

The provided headline discusses GH Power and TKMS exploring clean energy collaboration for Canada's submarine project, which has no apparent connection to Matinas BioPharma, a biopharmaceutical company. This disconnect suggests the stock's substantial 52.67% intraday gain was driven by catalyst(s) not captured in the news feed provided. For a small-cap biotech trading at $0.32, typical catalysts include positive clinical trial announcements, FDA approvals or positive guidance, partnership or licensing deals, capital raises, or short-squeeze dynamics given potential high float ownership concentration. Without the actual relevant news, we cannot determine which factor drove today's move. The timing and magnitude suggest a material corporate event rather than pure technical momentum.

AXTI

AXT IncTechnology

$46.90+$19.64

+51.9%

NASDAQ · Mkt cap $3.7 B

AXT announced a long-term supplier agreement with Lumentum on July 29 and reported Q2 2026 financial results on July 30, likely driving the 51.86% gain as the contract signals major demand and revenue stability.

On July 29, AXT announced a definitive long-term supplier agreement with Lumentum Operations, a significant optoelectronics manufacturer. This type of multi-year supply contract typically signals strong future revenue visibility and customer confidence in AXT's compound semiconductor wafer substrates. The next day, AXT released its Q2 2026 earnings results. While the full financial details are not provided in the headlines, the timing of these two positive catalysts—a major supplier agreement followed immediately by earnings—appears to have triggered substantial investor enthusiasm. For a niche semiconductor supplier like AXT, long-term contracts with marquee customers are high-credibility signals of business momentum. The parallel strength in Lam Research (a semiconductor equipment supplier) reported on July 29 suggests broader sector tailwinds that may have aided sentiment. The combination of a definitive customer commitment and quarterly results likely created a positive narrative around AXT's growth prospects and financial health.

TONT.WT

Graf Global Corp.

$0.40+$0.20

+48.8%

CMCO

Columbus McKinnon Corp-NYIndustrials

$20.70+$6.06

+41.4%

NASDAQ · Mkt cap $526 M

Columbus McKinnon reported record Q1 fiscal 2027 orders and sales driven by the Kito Crosby acquisition, beat earnings and revenue estimates significantly, and raised full-year guidance, triggering a 41% stock surge.

Multiple earnings headlines from July 30 establish that CMCO delivered a strong quarter on the back of its Kito Crosby acquisition, which contributed a full quarter of results for the first time. The company posted record orders and sales, beat Wall Street expectations on both earnings (117.86% surprise) and revenue (7.30% surprise), and guided full-year fiscal 2027 outlook higher based on stronger demand and successful integration progress. Revenue grew 125% year-over-year to $531.5 million, with non-GAAP EPS of $0.61 also beating consensus. This constellation of positive data—acquisition accretion, top and bottom line beats, raised guidance—provides a clear fundamental catalyst for the move. The stock had already gained 27.3% earlier on the same day before the final guidance announcement, suggesting momentum built as details emerged.

WTER

Alkaline Water Co Inc-TheConsumer Defensive

$0.03+$0.01

+39.5%

NASDAQ · Mkt cap $1.1 M

No headlines were found in the last 48 hours, so the 39.53% gain in WTER cannot be directly attributed to any disclosed news event. The move likely reflects technical trading, short covering, or undisclosed rumors common in micro-cap stocks.

The absence of recent news headlines makes it impossible to identify a specific catalyst for WTER's sharp one-day gain. Alkaline Water is a micro-cap stock trading at $0.03, a price point where low absolute share counts and thin liquidity can produce outsized percentage moves on modest volume. Without access to intraday trading data, short-interest levels, or social media catalysts, several generic drivers remain plausible: a short squeeze or covering rally if short positions were significant, technical reversal following a prior downtrend, or word-of-mouth promotion in retail trading communities. The company itself operates in the specialty beverage sector, but without earnings reports, partnership announcements, or operational updates in the provided headlines, no fundamental catalyst can be identified. The rank as the 9th biggest gainer suggests the move was relative to market-wide activity rather than an isolated penny-stock anomaly, but that does not clarify the cause.

Missfresh LimitedCommunication Services

$9.20+$2.60

+39.4%

NASDAQ · Mkt cap $27 M

News headlines provided discuss Wendel's half-year results and an executive departure, but neither directly explains MF's 39% surge; the move likely reflects a separate catalyst not captured in the feed or delayed market response to undisclosed news.

The two news items in the 48-hour window concern Wendel (a European investment holding company), not Missfresh Limited directly. Wendel's half-year earnings release and David Darmon's announced November departure are unrelated to MF's business operations. While Wendel may hold a stake in MF or related entities, the headlines provided contain no explicit mention of MF, no earnings surprise, no guidance revision, and no operational catalyst tied to Missfresh itself. A 39% single-day gain for a retail grocery-delivery company of this magnitude typically reflects either a major earnings beat, strategic acquisition announcement, bankruptcy avoidance, or significant short squeeze. Without headlines documenting any of these, the true catalyst remains unknown. It is possible MF released separate earnings or guidance today, or that a rumor circulated outside the Yahoo Finance RSS feed tracked here.

CBRG

Chain Bridge IFinancial Services

$4.21+$1.18

+39.0%

RAM

Aries I Acquisition CorporationFinancial Services

$11.17+$3.14

+37.2%

SXTC

China SXT Pharmaceuticals IncHealthcare

$0.07+$0.02

+36.8%

NASDAQ · Mkt cap $2.4 M

No news was reported in the last 48 hours, so the 36.8% gain in SXTC shares cannot be directly attributed to a disclosed event. The move is likely driven by technical factors, unconfirmed rumors, or sector sentiment in small-cap biotech.

Yahoo Finance returned no headlines for SXTC in the past 48 hours preceding this snapshot. Without disclosed catalysts such as clinical trial results, regulatory approvals, partnership announcements, or earnings reports, the cause of the intraday surge remains unclear. SXTC trades at $0.07, indicating a micro-cap stock where price movements can be volatile and driven by low trading volume, retail interest, or speculation rather than fundamental news. Possible explanations include delayed reporting of company announcements not yet indexed by Yahoo's RSS feed, sector-wide momentum in Chinese pharma stocks, technical chart patterns attracting short-covering or momentum traders, or social media-driven retail attention. Without access to real-time company filings, insider activity, or social platforms, we cannot determine which factor or combination of factors drove the move.

KSCP

Knightscope, Inc.Industrials

$1.99+$0.49

+34.8%

NASDAQ · Mkt cap $26 M

Knightscope announced its Q2 2026 earnings conference call on July 30, and the stock surged 34.76%, likely driven by investor anticipation ahead of the results announcement rather than any disclosed earnings data itself.

The only headline provided is Knightscope's announcement that it will hold an earnings conference call to discuss Q2 2026 results. This is a procedural announcement, not the earnings release or results themselves. The substantial 34.76% gain on the same day as the call announcement suggests the market is either reacting to forward-looking optimism, a technical bounce in a micro-cap security, or positioned expectations about what the earnings call will reveal. Without the actual earnings results, guidance, or any other operational news in the provided headlines, the precise catalyst remains unclear. Micro-cap securities like KSCP can be volatile and may respond to announcement timing, short-covering, or sector momentum rather than fundamentals. The announcement alone does not establish what financial results or company developments might have driven the move.

COHU

Cohu IncTechnology

$46.51+$13.41

+33.4%

NASDAQ · Mkt cap $2.2 B

Cohu reported second quarter 2026 results on July 30, which likely drove the 33.38% gain as investors reacted to the earnings announcement released after market open.

Cohu, a semiconductor equipment and services supplier, announced its Q2 2026 fiscal results on July 30, 2026 at 20:00 UTC, which aligns precisely with the snapshot date showing a massive intraday gain of 33.38%. The headline confirms net sales of $149 million were reported, though the full earnings details (EPS, guidance, margins, order trends) are not fully visible in the truncated news excerpt. The semiconductor equipment sector has been buoyed by AI chip demand, and a substantial single-day rally of this magnitude typically reflects either a significant earnings beat relative to expectations, positive forward guidance, or commentary about strong demand from AI-related semiconductor manufacturing. The other two news items about FormFactor and Wolfspeed are sector-adjacent but do not appear directly connected to Cohu's announcement. Without the complete earnings release showing margins, guidance, and management commentary, the exact driver cannot be pinpointed, but the timing and magnitude strongly suggest the Q2 earnings announcement itself was the catalyst.

SNDK

Sandisk CorporationTechnology

$1,279.96+$327.25

+32.4%

XRX

Xerox CorpIndustrials

$3.49+$0.85

+32.4%

NASDAQ · Mkt cap $402 M

Xerox crushed Q2 earnings expectations with a 500% earnings beat and raised full-year guidance, driven by Lexmark acquisition synergies and cost controls, triggering a 32% surge aided by short-squeeze dynamics.

Xerox reported second-quarter results on July 30 that significantly exceeded analyst expectations on earnings, with revenue up 22% year-over-year to $1.92 billion aided by the Lexmark acquisition integration. The company posted a +500% earnings surprise relative to estimates and raised full-year revenue and adjusted operating income guidance despite a 7% pro forma revenue decline, indicating strong margin expansion and operational leverage. Management highlighted cost synergies from the Lexmark deal, debt reduction efforts including the sale of tariff refund claims, and improved profitability. Multiple sources note the stock is heavily shorted, and the strong earnings result triggered a short squeeze that amplified the already positive reaction to the beat and guidance raise. This combination of earnings surprise, forward guidance improvement, and technical short-covering created the momentum for the substantial gain.

GCTK

GlucoTrack, Inc.Healthcare

$0.77+$0.16

+32.1%

NASDAQ · Mkt cap $3.7 M

GlucoTrack's subsidiary Lōkahi Therapeutics announced progress on LT-100 development toward single-injection administration on July 29, likely driving the 32% gain on July 30 as the market reacted positively to the clinical advancement.

The headline from July 29 indicates that Lōkahi Therapeutics, a wholly owned subsidiary of GlucoTrack, made a meaningful update to its LT-100 development strategy focused on evaluating a single-injection formulation. This type of announcement for a therapeutic candidate typically signals progress that reduces development risk and could accelerate commercial timelines, both factors that investors reward in small-cap biotech stocks. The timing aligns precisely with the stock's jump on July 30, the trading day following the announcement. The headline is truncated and does not provide full details of the development milestone, so the exact nature of the breakthrough is not entirely clear from the excerpt provided. However, movement from multi-dose to single-injection administration is generally viewed as a significant positive in drug development.

RACC

Research Alliance Corporation IIIFinancial Services

$21.90+$5.29

+32.1%

NASDAQ · Mkt cap $256 M

No news headlines were found in the last 48 hours, so the 32% gain cannot be attributed to a specific announced event; the jump may reflect delayed market reaction to an earlier announcement, technical trading activity, or sector momentum.

The absence of any news in the Yahoo Finance RSS feed over the last 48 hours means we cannot identify a specific catalyst for RACC's 32% single-day jump. This is a notable gap given the size of the move and the stock's ranking as the 19th biggest gainer. For a research alliance corporation, typical catalysts would include partnership announcements, funding closures, clinical trial results, or changes in research portfolio. The stock could be responding to a delayed reaction to news older than 48 hours, a technical bounce after prior weakness, short covering, or sector-wide momentum in biotech or research-focused equities. Without access to the full news archive or trading volume data, we cannot determine which mechanism is most likely at work here.

IREN

Iris Energy LimitedFinancial Services

$38.26+$9.58

+32.0%

NASDAQ · Mkt cap $18 B

IREN surged 32% today likely driven by a value realization trade after a recent 30% monthly selloff, with analyst commentary highlighting the stock's superior GPU partnerships and power portfolio relative to peers that have already rallied 50%+ in 2026.

The July 30 headline explicitly positions IREN as a "catch-up trade," noting that competitors TeraWulf and Cipher Mining have already gained over 50% this year while IREN remains in the red despite having superior fundamentals in GPU partnerships and power assets. This suggests the market may have been repricing IREN upward after recognizing a relative valuation disconnect. The prior day's headline about AI data center stocks being down 30% in a month contextualizes the recent weakness that preceded today's bounce. The Citadel forced asset sale mentioned on July 30 could have triggered broader portfolio rebalancing or reduced forced selling pressure in the sector, though no direct IREN impact is stated. The timing and framing of the catch-up trade commentary strongly suggests investor rotation back into a fundamentally-favored name after tactical overselling.

FCEL

FuelCell Energy IncIndustrials

$23.61+$5.61

+31.0%

NASDAQ · Mkt cap $1.2 B

FuelCell Energy surged 31% after Mizuho upgraded the stock and sector-wide enthusiasm from Bloom Energy's blowout Q2 earnings and raised guidance, driven by soaring AI data center power demand.

On July 30, FCEL rocketed 27-31% alongside peer Bloom Energy as a broad fuel-cell sector rally took hold. The immediate catalyst was Bloom Energy's blockbuster Q2 results released late July 29, which included an earnings surge of 680% and raised 2026 guidance well above consensus. More importantly, Goldman Sachs projects U.S. data center power demand could double from 31 gigawatts in 2025 to 66 gigawatts by 2027 as AI infrastructure expands, with data centers potentially accounting for 20% of total U.S. power demand. A fresh Mizuho analyst upgrade on FCEL itself helped amplify the move. The story here is sector-wide: fuel cells and distributed power generation play a critical role in meeting explosive AI-driven electricity demand. FCEL appears to have benefited from both direct analyst action and positive spillover from Bloom's successful quarter and forward guidance, which validates the structural AI power thesis for the entire sector.

NBIS

Nebius Group N.V.Communication Services

$188.42+$46.71

+31.0%

NASDAQ · Mkt cap $61 B

Nebius surged 31% on a combination of a Wall Street analyst upgrade to Buy, broad recovery in AI infrastructure stocks following sector-wide selling pressure, and continued momentum from major enterprise partnerships including Meta spending estimates over $60 billion.

The jump appears rooted in multiple convergent catalysts rather than a single event. Freedom Capital upgraded NBIS to Buy on July 30, which typically anchors intraday rallies. More broadly, the headlines establish that AI cloud and infrastructure stocks experienced violent whipsawing overnight followed by a snap-back recovery on July 30, with NBIS gaining alongside peers like CoreWeave. The Meta partnership news citing potential $62 billion in spending with both CoreWeave and Nebius provided fresh conviction on enterprise demand. Headlines also reference July as a month of pain for the stock, suggesting the 31% gain partially represents forced-liquidation reversal and technical rebound rather than purely new bullish fundamental change. One article explicitly notes the stock still screens as undervalued on multiples despite its surge, implying recovery from oversold conditions rather than a fresh catalyst materializing.

FRVO

Fervo Energy CompanyUtilities

$22.30+$5.23

+30.6%

NASDAQ · Mkt cap $5.1 B

No news headlines were available in the last 48 hours, so the 30.61% jump cannot be directly attributed to a reported event. The move likely reflects either delayed market reaction to an announcement, technical trading activity, or sector-related momentum in geothermal energy.

Fervo Energy is a geothermal power developer that went public via SPAC merger. With zero news in the Reuters/Yahoo Finance feed over the past two days, the catalyst for a top-25 daily gain remains opaque from published sources. However, geothermal stocks can be volatile and responsive to: changes in renewable energy policy or investment narratives, analyst upgrades not yet reflected in feeds, insider transaction disclosures, technical chart breakouts triggering momentum buying, or delayed reaction to an announcement made just outside the 48-hour window. Given Fervo's small float and early-stage profile, even modest positive developments can spark outsized percentage moves. Without access to real-time trading data, regulatory filings, or financial news beyond the provided sources, the specific trigger cannot be determined from available evidence.

PLPC

Preformed Line Products CoIndustrials

$369.97+$86.18

+30.4%

NASDAQ · Mkt cap $1.9 B

Preformed Line Products reported record Q2 2026 earnings with strong revenue and earnings growth driven by energy demand and AI-related business expansion, triggering a 30% stock surge on the positive earnings surprise and strong forward signals.

The three headline sources all converge on the same catalyst: PLPC announced record second quarter 2026 financial results on July 29-30. The earnings report highlighted year-over-year growth in revenue and earnings, higher profit margins, and strong global expansion. Notably, one headline explicitly ties the business boom to the AI revolution, suggesting that demand for PLPC's infrastructure products (preformed line products serve telecom, power, and data center applications) is benefiting from accelerated AI and data center buildout. The magnitude of the move (30.37%) is consistent with a strong earnings beat combined with forward guidance that suggests sustained momentum. No specific earnings-per-share beat percentage or revenue guidance revision is detailed in these headlines, but the language of "record results" and the AI narrative appear sufficient to justify the enthusiasm.

Bloom Energy CorpIndustrials

$207.02+$50.19

+30.2%

NYSE · Mkt cap $74 B

Bloom Energy surged 30% after posting record Q2 revenue and raising guidance, combined with a Mizuho upgrade to Outperform with a $242 price target citing stronger execution and margin expansion.

The move is grounded in two concrete catalysts. First, Bloom Energy reported blockbuster Q2 results with record revenue and raised full-year guidance, though the market took a day to fully absorb the strength. Second, and more immediately, Mizuho upgraded the stock from Neutral to Outperform on July 30, setting a $242 price target implying 48% upside from the prior close. The analyst cited stronger-than-expected execution, accelerating margin expansion, and improving operating leverage. One headline notes that retail investors are fleeing despite the strong results, suggesting institutional demand from the upgrade may have overwhelmed retail selling pressure. The fuel-cell sector rallied broadly alongside BE, indicating positive sentiment spillover in the alternative energy space.

LUNG

Pulmonx CorpHealthcare

$1.62+$0.37

+29.9%

NASDAQ · Mkt cap $99 M

Pulmonx beat Q2 revenue estimates by 2.34% and delivered a positive earnings surprise of 14.29%, while management highlighted progress in rebuilding the U.S. sales organization, likely triggering the 29.9% jump on July 30.

Pulmonx reported second-quarter results on July 29 that exceeded analyst expectations on both earnings and revenue metrics. The company posted $22.8 million in Q2 revenue and reiterated its full-year 2026 guidance, signaling management confidence despite operating losses. The earnings call highlighted concrete operational progress, specifically rebuilding efforts in the U.S. sales organization, which appears to have resonated with investors as evidence of execution on a turnaround. For a stock trading at $1.62, a beaten earnings report combined with constructive management commentary on sales infrastructure can trigger outsized percentage moves, especially if short interest or technical positioning had been unfavorable. The timing of the earnings release on July 29 evening followed by a 29.9% jump on July 30 is consistent with a post-earnings rally driven by positive surprise and forward-looking confidence signals.

MKTX

MarketAxess Holdings IncFinancial Services

$162.81+$37.11

+29.5%

NASDAQ · Mkt cap $5.7 B

Intercontinental Exchange announced a definitive agreement to acquire MarketAxess for $167 per share in cash, representing a 33% premium to Wednesday's close and explaining the 29.52% single-day surge.

The acquisition announcement by ICE is the clear and direct catalyst for MKTX's gain. Multiple headlines confirm that ICE agreed to pay $167 per share in an all-cash transaction valued at approximately $6 billion in equity value. This represents a substantial premium to the stock's prior trading price, which is typical for acquisition announcements. The timing coincided with MarketAxess releasing Q2 earnings that beat both revenue and EPS estimates, though the earnings results themselves appear secondary to the transformational M&A news. The acquisition price of $167 sits slightly above the current trading price of $162.81, suggesting the market is pricing in some execution risk or deal uncertainty, though the bulk of the expected gain has already been captured in today's move.

WYTC

WYTEC INTERNATIONAL INC

$1.23+$0.28

+29.5%

NASDAQ

No news headlines were found in the last 48 hours, so the 29.47% gain cannot be directly attributed to a specific company announcement or market event. The jump likely stems from technical buying, retail interest, or unverified rumors.

The absence of any Yahoo Finance headlines in the 48-hour window prior to this +29.47% rally is striking for a stock that ranked 28 among daily gainers. WYTEC trades at $1.23, placing it in the microcap/penny stock range where price movement is often driven by factors other than fundamental news. Without documented catalysts, this gain most likely reflects one of three mechanisms: (1) technical bounce from oversold conditions or momentum buying in a thinly traded security, (2) retail social media chatter or coordinated buying outside traditional news channels, or (3) delayed disclosure of corporate developments that have not yet been picked up by major news feeds. Small-cap stocks frequently experience sharp intraday swings on minimal volume and speculative interest rather than company-specific events.

KEEL

Keel Infrastructure Corp.Technology

$4.05+$0.95

+29.2%

NASDAQ · Mkt cap $2.0 B

No news headlines were found in the last 48 hours, so the 29% gain likely reflects either a delayed market reaction to an untracked announcement, technical trading, or sector-specific momentum for infrastructure stocks.

The complete absence of recent Yahoo Finance headlines covering KEEL makes it difficult to pinpoint a specific catalyst for the 29% single-day jump. Keel Infrastructure Corp. is a smaller-cap infrastructure company, and such stocks can experience sharp moves on limited news flow or delayed information dissemination. Possible explanations include a contract announcement or earnings release that did not immediately appear in the RSS feed sampled, a technical or short-squeeze rebound off previous lows, or sector-wide positive sentiment toward infrastructure spending. Without corroborating headlines or structural data (bid-ask spread, float size, short interest), attributing the move to any specific event remains speculative.

ONTX

Onconova Therapeutics IncFinancial Services

$13.72+$3.10

+29.1%

BHC

Bausch Health Cos IncHealthcare

$6.03+$1.34

+28.6%

NYSE · Mkt cap $2.5 B

Bausch Health delivered a strong Q2 earnings beat with 31% EPS surprise and raised full-year 2026 guidance, driven by growth across Salix, Solta Medical, and Bausch + Lomb divisions, sparking a 28.6% single-day rally.

The earnings announcement released on July 29-30 established that BHC beat both revenue and earnings estimates, with the company extending a 13-quarter streak of consecutive revenue and adjusted EBITDA growth. Management raised 2026 revenue and EBITDA guidance following the strong performance. The size of the move—ranking as the 31st biggest gainer on the day—aligns with a substantial positive earnings surprise combined with proactive guidance elevation. The 31.25% EPS beat is material and represents genuine outperformance relative to consensus expectations. Note that healthcare stocks broadly declined 1.5% that afternoon, yet BHC surged, indicating the earnings strength was company-specific rather than sector-driven. The guidance raise is particularly notable as it signals management confidence in sustained momentum.

APMI

AxonPrime Infrastructure Acquisition Corporation Class A Common Stock

$16.78+$3.73

+28.6%

ZTG

Zenta Group Company LimitedIndustrials

$3.49+$0.77

+28.3%

NASDAQ · Mkt cap $30 M

No news headlines were found in the last 48 hours, so the 28.31% gain cannot be attributed to a specific announced event. The move likely reflects technical trading, delayed news dissemination, or an undisclosed catalyst.

ZTG jumped 28.31% to rank 33rd among daily gainers, yet no recent news articles appear in the provided Yahoo Finance feed covering the last 48 hours. This disconnect between the large price movement and absence of headline coverage creates ambiguity about the underlying catalyst. Small-cap stocks like ZTG can be subject to short covering, retail trader attention following momentum, sector rotation, or delayed media pickup of earlier announcements. Without specific earnings reports, regulatory approvals, partnership announcements, or guidance changes visible in the news sources provided, we cannot pinpoint a fundamental driver. The lack of contemporaneous headlines suggests either the catalyst predates the 48-hour window, market participants are acting on non-public information or rumors, or the move is primarily technical in nature rather than news-driven.

FXHO

Utime Ltd.Technology

$11.98+$2.63

+28.1%

NASDAQ · Mkt cap $54 M

No news headlines were found in the last 48 hours for FXHO, so the 28% gain cannot be directly attributed to a disclosed event; the move likely reflects either delayed news dissemination, technical/short squeeze activity, or a material announcement not yet indexed by Yahoo Finance.

The absence of any recent news headlines despite a 28% single-day surge is unusual and suggests several possible explanations. First, Yahoo Finance's RSS feed may have a lag in indexing breaking news, meaning an announcement was made but not yet captured in the provided data. Second, small-cap stocks like Utime Ltd. are susceptible to technical rallies, short squeezes, or retail trading bursts that can occur without accompanying material news. Third, the move could reflect resolution of a pending corporate action, regulatory approval, or earnings release that occurred within the snapshot window but before news aggregation. Without access to the company's investor relations page or real-time news feeds, it is impossible to determine whether this is a fundamental catalyst or momentum-driven trading. The rank as the 34th biggest gainer suggests the move is statistically significant but does not itself explain the mechanism.

CIFR

Cipher Mining Inc.Technology

$22.66+$4.95

+27.9%

NASDAQ · Mkt cap $7.2 B

Cipher Mining surged 27.92% on positive AI infrastructure sentiment and a Morgan Stanley note highlighting upside from ERCOT grid classifications that strengthen its competitive position in Texas data center expansion.

The headlines establish that Morgan Stanley published research on July 30 identifying Cipher Mining as a beneficiary of ERCOT's 65 GW Batch Zero classifications, which could strengthen its grid position while pressuring Texas power prices. This is a concrete, analyst-endorsed positive catalyst for a company heavily exposed to AI infrastructure buildout. Concurrently, a broader sentiment piece from the same day emphasizes forced selling creating opportunity in AI infrastructure stocks, and a comparison note positions Cipher Mining as significantly outperforming alternatives like IREN year-to-date despite IREN's stronger partnerships. The timing of the Morgan Stanley research on the day of the move, combined with the broader AI infrastructure rebound narrative, provides a grounded explanation for the 28% jump.

WYFI

WhiteFiber, Inc.Technology

$26.24+$5.68

+27.6%

NASDAQ · Mkt cap $730 M

No news headlines were published in the last 48 hours, so the +27.63% gain cannot be attributed to a specific announced catalyst. The move likely reflects delayed market reaction to prior news, technical or short-covering activity, or an untracked announcement.

WhiteFiber experienced a substantial single-day gain of +27.63%, ranking it among the day's top 36 gainers, yet no news headlines appear in the last 48 hours of coverage. This disconnect suggests several possibilities. First, a material announcement may have occurred but not yet indexed by the news aggregator. Second, the move could reflect delayed market pricing of information released earlier than the 48-hour window. Third, given that WhiteFiber appears to operate in the fiber-optic or broadband infrastructure space, the stock may be responding to sector tailwinds, contract wins, or regulatory developments that have not been formally announced. Finally, for a stock of this size and price level, technical factors such as short covering, options-related gamma moves, or retail accumulation cannot be ruled out. Without contemporaneous news, pinpointing the precise cause is not possible.

CORT

Corcept Therapeutics IncHealthcare

$118.38+$25.47

+27.4%

NASDAQ · Mkt cap $12 B

Corcept reported strong Q2 earnings with revenue up 32% to $256.1 million, beat analyst estimates, and raised full-year 2026 guidance, driven by robust Cushing's syndrome sales and a successful Lifyorli launch.

The evidence clearly establishes that Corcept released second-quarter 2026 financial results on July 29-30, 2026 that exceeded market expectations. Revenue surged 32% year-over-year to $256.1 million, beating estimates by approximately 18%, while the company also reported earnings that surprised positively. The company's Cushing's syndrome franchise performed strongly, and the newly launched Lifyorli product contributed meaningfully to revenue growth. Management responded to these results by raising full-year 2026 revenue guidance. Multiple sources confirm that Wall Street provided support following this earnings announcement, with the 27.4% single-day gain representing the stock's best performance in nearly 16 months. The timing of the news release on July 29 evening and the stock's climb to a 52-week high on July 30 aligns perfectly with typical post-earnings momentum.

SFWL

Shengfeng Development Limited - Class A Ordinary SharesIndustrials

$1.02+$0.22

+27.4%

NASDAQ · Mkt cap $73 M

No news headlines were found in the last 48 hours, so the 27.37% jump in SFWL likely stems from technical factors, delayed market reaction to an earlier event, or market rumors not yet captured in major news feeds.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for this substantial single-day gain. SFWL is a Chinese development company listed on NASDAQ, and stocks in this category can be sensitive to several types of unlisted catalysts: delayed reporting of earnings or guidance changes from investor calls, short covering or momentum trading in a thinly traded name, geopolitical or regulatory developments in China that spread through social media or trading communities before reaching mainstream financial media, or simply technical rebound after prior weakness. The 27.37% jump is significant enough that it likely reflects real information or positioning rather than pure random noise, but without corroborating headlines, we cannot determine which of these categories applies. Investors should verify whether company filings, press releases on the firm's own website, or Chinese-language sources have announced material news not yet picked up by English-language financial news aggregators.

HAVAR

Harvard Ave Acquisition Corporation Rights that convert on a 1/10th of 1 basis to Class A ordinary Shares

$0.15+$0.03

+27.1%

NASDAQ

No news headlines were found in the last 48 hours, so the 27% gain in HAVAR rights is unexplained by reported corporate events. The move likely reflects either technical trading activity in a low-float SPAC vehicle or delayed market reaction to an earlier announcement.

HAVAR is a SPAC rights instrument converting at a 1/10th ratio to Class A ordinary shares, a security type that typically trades with low volume and can exhibit outsized percentage moves on modest absolute price changes. The stock rose $0.04 in absolute terms, a small move in dollar value that translates to a large percentage gain in a penny-range security. With zero news reported in the 48-hour window, the catalyst remains unknown. Possible explanations include: first, a technical or momentum-driven move in a thinly-traded SPAC vehicle, which can spike on minimal buying pressure; second, a delayed market reaction to news or announcements made earlier than the 48-hour RSS window; third, activity related to SPAC warrant or rights redemption dynamics, or speculation about a pending de-SPAC event. Without current headlines or structural insight into HAVAR's specific situation, attribution is speculative.

BRUN

Boost Run Inc.Technology

$19.83+$4.20

+26.9%

NASDAQ · Mkt cap $1.4 B

No news headlines were found in the last 48 hours, so the 26.87% jump in BRUN stock cannot be tied to a specific announced event. The move likely reflects technical buying, a delayed announcement, or market rumor.

The absence of recent news headlines creates a significant gap in explaining this substantial single-day gain. Without access to press releases, SEC filings, or earnings announcements, the most probable categories of catalyst are technical in nature—such as short covering, options expiration effects, or algorithmic buying triggered by price momentum—or event-driven but not yet reflected in major financial news feeds. Alternatively, the stock could have responded to a company announcement or market development that has not yet been picked up by the RSS feed lag, or to rumors circulating in retail or institutional channels. For a smaller-cap or lower-liquidity stock like BRUN, even modest buying volume can produce outsized percentage moves. Without concrete information, any specific explanation remains speculative.

NEXR

Nexera Technologies Ltd.Consumer Cyclical

$0.38+$0.08

+26.8%

ALAB

Astera Labs, Inc.Technology

$299.57+$67.22

+26.6%

NASDAQ · Mkt cap $53 B

Astera Labs surged 26.59% on July 30 following a sector-wide chip stock rally and renewed investor focus on its 115% revenue growth and 25.7% net margins ahead of August 4 earnings.

The jump appears rooted in two reinforcing dynamics. First, the broader tech sector rebounded sharply on July 30 with chip stocks leading, and Astera was highlighted as a standout performer in that group. Second, multiple headlines from July 28-30 emphasize Astera's exceptional profitability metrics—115% revenue growth paired with positive 25.7% net margins and zero debt—positioning it favorably against peer comparisons. The Aug. 4 earnings date looms as a key risk-reward moment; investors appear to be re-rating the stock ahead of that catalyst after a 4% pullback on July 29. No specific new company announcement is evident, so the move is best explained as sector momentum plus renewed confidence in Astera's financial strength as earnings approach.

FORM

FormFactor IncTechnology

$105.35+$22.01

+26.4%

NASDAQ · Mkt cap $7.6 B

FormFactor reported Q2 earnings that beat estimates with record revenue of $258.2 million (up 31.9% YoY), strong AI-driven demand across HBM and data-center products, and raised guidance for Q3, directly explaining the 26.41% gain.

The earnings release on July 29-30 established multiple bullish facts: revenue surprise of +7.55%, earnings surprise of +34.43%, sequential revenue growth of 14% to record levels, and demonstrated strength in high-bandwidth memory and AI-related semiconductor testing segments. Management's raised outlook for the next quarter signals confidence in sustained momentum. The Keystone Microtech capacity expansion pact announced the same day further reinforces positioning in AI and advanced packaging test markets. One comparative article briefly noted a competitor's relative strengths, but this was clearly secondary to FormFactor's own strong execution and forward guidance. The magnitude of the move aligns with both the earnings beat magnitude and the raised guidance, suggesting the market's reaction is proportionate to disclosed fundamentals.

BGDE

Big Digital Energy, Inc.Financial Services

$5.79+$1.19

+25.8%

NASDAQ · Mkt cap $41 M

No headlines were found in the last 48 hours for BGDE, so the 25.76% single-day gain cannot be directly attributed to disclosed news. The jump may reflect technical trading, a delayed announcement, or sector momentum.

The absence of recent news coverage for a 25.76% intraday gain on a relatively small-cap stock like BGDE (ranked 44th of the day's gainers) makes it difficult to pinpoint a specific catalyst. For stocks in the energy sector, typical catalysts include oil price movements, contract wins, earnings surprises, or regulatory actions, but none appear in the available headlines. The stock's modest price level of $5.79 and the sharp percentage move suggest it may be responsive to technical factors, short-squeeze activity, or unannounced company developments that have not yet propagated to major financial RSS feeds. It is also possible that news broke via the company's own channels or secondary sources but has not yet been indexed by Yahoo Finance RSS within the 48-hour window.

AIBZ

Bitzero Holdings Inc.Technology

$6.65+$1.34

+25.1%

NASDAQ · Mkt cap $363 M

Bitzero announced the closing of a US$25 million private placement on July 30, which likely triggered the 25% gain as investors responded positively to the capital raise and de-risking of the company's balance sheet.

The news timeline shows Bitzero announced a US$25 million private placement on July 29 and then announced its closing on July 30, the same day as the stock's 25% jump. For early-stage or capital-constrained companies in the HPC and AI infrastructure space, a successful capital raise of this magnitude is typically viewed as a significant positive event because it reduces near-term dilution risk, extends runway, and signals investor confidence. The fact that the placement closed quickly (within one day of announcement) suggests strong demand and execution, which reinforces the bullish signal. The stock's ranking as the 45th biggest gainer on the day is consistent with a company-specific capital event rather than broad market movement.

NUAIW

New Era Helium Inc WarrantsTechnology

$2.18+$0.43

+24.6%

AAOI

Applied Optoelectronics IncTechnology

$90.05+$18.79

+24.5%

NASDAQ · Mkt cap $8.9 B

Applied Optoelectronics surged 24.49% on valuation research suggesting the stock is undervalued by approximately 26% based on discounted cash flow analysis, triggering renewed investor interest.

Two analyst reports published on July 29th focused on AAOI's valuation fundamentals rather than operational news. The first headline explicitly states that cash flow-based intrinsic value analysis suggests the stock trades 26% below fair value. The second mentions a "valuation split" and frames recent pullback as a potential buying opportunity, indicating contrarian positioning. These pieces appear to have circulated among retail and institutional investors on July 30th, generating sufficient buying interest to rank the stock 47 in daily gainers. The timing and content suggest algorithmic buying triggered by positive valuation narratives rather than company-specific earnings, contract wins, or guidance changes. No operational catalyst is evident in the headlines provided.

BTDR

Bitdeer Technologies Group - Ordinary SharesTechnology

$11.10+$2.18

+24.4%

NASDAQ · Mkt cap $2.6 B

No news directly tied to Bitdeer was provided; the 24.38% surge likely reflects a technical catalyst, sector momentum in crypto mining, or delayed announcement coverage not yet captured in the headlines supplied.

The single headline provided discusses Active Energy Group's UAE infrastructure pipeline expansion, which is unrelated to Bitdeer Technologies Group, a Bitcoin mining and infrastructure company. This suggests either that relevant Bitdeer-specific news was not captured by the RSS feed snapshot, or that the move was driven by a non-news catalyst. Bitdeer stock typically responds to fluctuations in Bitcoin price, mining difficulty and hashrate trends, regulatory developments in crypto mining jurisdictions, or earnings and guidance announcements. A 24% single-day jump of this magnitude in a mining stock could reflect a significant announcement regarding mining operations, hashrate expansion, strategic partnerships, or a broad rally in the digital assets sector. Without headline evidence directly attributable to Bitdeer, the precise trigger remains unclear.

MNDR

Mobile-health Network SolutionsHealthcare

$1.75+$0.34

+24.1%

NASDAQ · Mkt cap $2.0 M

No news headlines were found in the last 48 hours, so the 24% jump in MNDR cannot be attributed to a specific disclosed event. The move may reflect technical trading, delayed news absorption, or market speculation.

The absence of recent news headlines makes it difficult to pinpoint a concrete catalyst for MNDR's 24% gain on 2026-07-30. Mobile-health and telehealth stocks have historically been sensitive to regulatory announcements, reimbursement policy changes, partnership deals, and clinical trial results. Given that MNDR ranks 49th among daily gainers but has no corresponding headline coverage in the provided feed, the move could stem from several sources: a press release or earnings report not yet indexed by the news feed, technical momentum or short covering in a lower-liquidity stock, anticipation of an upcoming event, or social media-driven retail interest. Without corroborating news, we cannot definitively separate signal from noise.

ARAY

Accuray IncHealthcare

$0.29+$0.06

+24.0%

NASDAQ · Mkt cap $35 M

Accuray announced financial strengthening agreements with TCW Asset Management and a comprehensive strategic plan to improve financial position and liquidity, triggering a 23.96% gain despite broader healthcare sector weakness Thursday.

On July 29 and July 30, Accuray disclosed two related developments: a plan involving financial strengthening, strategic partnerships, technology rollouts, and operational initiatives to drive long-term value creation, followed by definitive agreements with TCW Asset Management specifically designed to boost financial position and liquidity. For a micro-cap stock trading at $0.29, capital infusion announcements and financial restructuring plans can generate substantial relief rallies, particularly when they address solvency or liquidity concerns. The stock's outperformance against the broader healthcare sector decline (which fell 1.7% Thursday) suggests investors are responding positively to company-specific news rather than sector momentum. The lack of detail in the available headlines prevents identification of exact deal terms, but the framing around "financial strengthening" and "liquidity" implies the company may have faced previous cash constraints or balance sheet concerns that this partnership addresses.

Biggest Losers

Thu, Jul 30, 2026 50

KPTI

Karyopharm Therapeutics IncHealthcare

$7.00−$4.69

-68.4%

NASDAQ · Mkt cap $45 M

Karyopharm announced topline Phase 3 trial results in endometrial cancer and plans for an sNDA submission in myelofibrosis, but the 68% intraday collapse suggests the trial results likely missed primary endpoints or efficacy expectations, triggering heavy selling despite the positive regulatory p…

Karyopharm released two pieces of news on July 30: topline results from the Phase 3 XPORT-EC-042 trial in endometrial cancer and plans to submit a supplemental application for selinexor plus ruxolitinib in myelofibrosis under accelerated approval. The magnitude of the stock's decline (ranked 1 biggest loser) is inconsistent with purely positive news. While the headlines provided do not include the actual trial outcomes or efficacy data, a 68% single-day drop strongly suggests the endometrial cancer trial failed to meet its primary endpoint or showed efficacy below market expectations. The accelerated approval pathway announcement appears insufficient to offset disappointing Phase 3 results. Biotech stocks typically respond sharply to Phase 3 trial outcomes, particularly when they miss, since such trials are pivotal for regulatory approval and commercial viability.

CCB

Coastal Financial Corp-WAFinancial Services

$39.84−$30.70

-43.5%

YYAI

Connexa Sports Technologies Inc.Technology

$0.17−$0.12

-42.4%

NASDAQ · Mkt cap $3.9 M

AiRWA Inc. (ticker YYAI) announced completion of its acquisition of Hong Kong Best Life Trade Co., which likely triggered a sharp 42% sell-off due to investor concerns about deal value, integration risk, or dilution from the transaction structure.

The headline confirms that AiRWA completed a previously announced acquisition of Best Life on July 30, 2026. The timing of the announcement coinciding with the largest single-day drop suggests the market is reacting negatively to either the completion itself or details revealed at closing. Possible drivers include disappointment with the acquired company's financial performance, concerns about overpayment, unexpected dilution to existing shareholders from financing the deal, or poor strategic fit. Without access to the full press release text or investor guidance, we cannot determine whether the market feared integration challenges, cash burn, or execution risk. The magnitude of the decline is severe enough to suggest material negative surprise rather than routine deal completion.

CAPR

Capricor Therapeutics IncHealthcare

$4.17−$2.38

-36.3%

NASDAQ · Mkt cap $464 M

Capricor's stock plummeted 36% after the FDA advisory committee voted negatively on its Deramiocel therapy for Duchenne muscular dystrophy, despite the company's recent Lancet publication and CEO confidence in approval odds.

The headlines establish that Capricor held a critical FDA advisory committee meeting on July 29-30, 2026, and the panel rendered a negative recommendation on Deramiocel. This is a major setback for a clinical-stage biotech company where regulatory approval is the primary value driver. The company had attempted to shore up confidence with a Lancet publication of HOPE-3 trial data and statements reinforcing approval prospects, but the advisory committee's skepticism—reportedly focused on how Capricor analyzed the late-stage trial results—overrode those efforts. One analyst quoted in the headlines suggested a $2 price target (down from $4.17), while some retail investors retained hope for a narrower, upper-limb focused approval. The stock is now headed for its worst week on record, indicating a sharp repricing of approval probability.

INO

Inovio Pharmaceuticals IncHealthcare

$0.66−$0.37

-35.9%

NASDAQ · Mkt cap $134 M

Inovio announced a $20 million public offering on July 30, which likely triggered heavy selling due to shareholder dilution concerns and typical biotech market weakness surrounding equity raises.

On July 29, Inovio announced a proposed public offering, followed by pricing confirmation on July 30 at $20 million. Public offerings by small-cap biotech firms typically trigger sharp declines because they signal dilution of existing shareholders and often indicate capital strain. The stock's 35.92% single-day drop on the announcement is consistent with market reaction to equity raises in this sector. The company framed itself as focused on DNA medicines for HPV-related diseases and infectious diseases, suggesting it remains in development stage with ongoing cash burn. No details were provided in the headlines about offer price, number of shares, or use of proceeds, which prevents deeper analysis. However, the timing and magnitude of the move align directly with the news cycle and the structural dynamics of biotechnology equity offerings.

MYGN

Myriad Genetics IncHealthcare

$5.37−$1.73

-33.5%

NASDAQ · Mkt cap $292 M

Myriad Genetics fell 33.53% after reporting Q2 2026 revenue of $190.7 million, missing analyst estimates and declining 10.5-11% year-over-year due to lower test volumes and reduced average revenue per test.

The earnings report released on July 30 disclosed that Myriad Genetics missed revenue expectations for Q2 2026. The company reported $190.7 million in quarterly revenue, representing an 11% year-over-year decline driven by a 1% volume decline and a 9% decrease in average revenue per test. This combination of top-line miss and negative year-over-year growth suggests weakening demand and pricing pressure in the genetic testing market. The stock dropped 28.6% on the headline earnings news itself, with the additional 33.53% total daily decline indicating that either broader market forces acted on the stock later in the session or that the initial reported drop has compounded further. The company's announcement of "new initiatives focused on driving increased efficiency" suggests management acknowledges operational challenges requiring structural response.

Goldfield Corp-TheConsumer Defensive

$0.14−$0.07

-32.9%

NASDAQ · Mkt cap $157 K

The provided news concerns Visionary Holdings' subsidiary and a stem cell product distribution agreement in China, which appears unrelated to Goldfield Corp. The 32.9% drop likely stems from other undisclosed catalysts or market conditions not covered in the headlines provided.

The single headline in the news feed describes a distribution partnership between a Visionary Holdings subsidiary and a Chinese healthcare network for stem cell aesthetic products. This news has no apparent connection to Goldfield Corp (GV), a gold mining company. The headline does not mention Goldfield, gold prices, mining operations, or any related business. Given that GV is ranked as the seventh biggest loser on the day with a sharp 32.9% decline, the cause appears to be something else entirely. Possible drivers could include a significant drop in gold prices, disappointing quarterly earnings or production guidance, operational issues at mining facilities, or adverse regulatory developments in jurisdictions where Goldfield operates. Without relevant news directly tied to Goldfield, the exact catalyst remains unclear from the evidence available.

GBFH

GBank Financial Holdings Inc.Financial Services

$20.93−$9.22

-30.9%

NASDAQ · Mkt cap $311 M

GBank Financial reported Q2 earnings that missed both top and bottom-line estimates, with earnings down 24% versus expectations, triggering the sharp decline as investors reacted to disappointing profitability and credit quality pressure.

The stock plunged 30.92% following GBank Financial's Q2 2026 earnings release on July 29. The company reported net income of $5.5 million or $0.38 per diluted share, but this represented a 24% earnings miss versus analyst estimates. Revenue also came in 1.13% below expectations. The earnings call highlighted credit quality pressures and gaming-card revenue headwinds, suggesting operational challenges beyond a simple miss. While the company noted SBA lending growth and progress in gaming fintech strategy, these positives were apparently outweighed by the earnings shortfall and forward-looking concerns about asset quality. The magnitude of the earnings miss, combined with cited credit pressures, likely convinced investors that profitability deterioration may extend into coming quarters.

ATXI

Avenue Therapeutics IncHealthcare

$0.25−$0.11

-29.7%

NASDAQ · Mkt cap $824 K

No news headlines are available from the past 48 hours for ATXI, so the 29.74% single-day drop cannot be attributed to a specific disclosed event. The decline likely reflects either a delayed market reaction to older news, a technical or short-squeeze event, or a company-specific catalyst not yet…

Avenue Therapeutics is a small-cap biopharmaceutical company where stock price movements of this magnitude are common even absent major headline news. Without any recent earnings, FDA decisions, clinical trial results, partnership announcements, or guidance changes visible in the provided news feed, the catalyst remains opaque. For biotech microcaps, common drivers of sharp single-day declines include negative clinical data or regulatory setbacks that have not yet propagated to major news wires, insider selling, warrant exercises, dilutive financing, or technical breakdown in a thinly-traded stock. This is inference rather than established fact. The absence of news does not rule out a material event; it may simply not yet be reflected in the RSS feed or may be developing.

BIYA

Baiya International Group Inc. Ordinary SharesTechnology

$3.77−$1.67

-29.6%

NASDAQ · Mkt cap $71 M

No news headlines were found in the last 48 hours to explain BIYA's 29.56% drop, so the cause remains unclear without additional reporting on earnings, guidance changes, regulatory issues, or broader market events.

The absence of any recent news headlines makes it impossible to identify a specific catalyst for this sharp decline. BIYA is a small-cap Chinese company trading on NASDAQ, and stocks of this profile can experience large single-day moves for several reasons: delayed earnings disappointment or guidance cut released outside the normal news cycle, sudden delisting warnings or regulatory pressure from Chinese authorities, short-squeeze unwinding after earlier gains, sector rotation out of China-exposed equities, or execution of a known capital action like a secondary offering. Without access to company filings, SEC documents, or news beyond the provided RSS feed, we cannot determine which category applies. The magnitude of the move suggests something material rather than purely technical, but that remains inference rather than established fact.

FCRS.WT

FutureCrest Acquisition Corp. WT

$0.73−$0.25

-29.4%

TDOC

Teladoc Health IncHealthcare

$6.58−$2.63

-28.5%

NYSE · Mkt cap $1.2 B

Teladoc reported Q2 earnings that beat on adjusted earnings but missed on revenue and lowered full-year 2026 guidance due to BetterHelp demand headwinds, triggering a 28.5% decline despite positive market conditions for tech stocks.

Teladoc released Q2 2026 results on July 29-30 showing mixed fundamentals. While the company beat adjusted earnings estimates, it missed revenue expectations with sales of $606.9 million and posted a wider net loss. More critically, management lowered 2026 full-year revenue guidance to $589 million for Q3, signaling weakness ahead. The primary culprit was BetterHelp, Teladoc's mental health unit, which experienced unexpected demand shifts as insurance-covered offerings accelerated faster than expected, cannibilizing higher-margin cash-pay revenue. One analyst called this an "unfortunate setback." Notably, the stock declined sharply despite a favorable macro backdrop where the Nasdaq rallied on semiconductor strength and Microsoft surged 15%, suggesting the guidance cut and BetterHelp concerns specifically outweighed positive tech sector sentiment. The revenue miss coupled with lowered forward guidance appears to have driven the sell-off despite profitability metrics beating expectations.

ALNY

Alnylam Pharmaceuticals IncHealthcare

$205.59−$81.65

-28.4%

NASDAQ · Mkt cap $36 B

Alnylam fell 28% despite beating revenue expectations and posting record Amvuttra sales, likely due to full-year guidance reduction and investor concerns about normalizing second-line drug demand going forward.

The earnings headlines present a mixed picture. On the positive side, Q2 2026 revenue surged 74% to $1.2 billion and Amvuttra delivered record results, beating expectations. However, the company lowered its full-year 2026 guidance, citing normalization of second-line demand for its main drug. The headline "Alnylam plunges as earnings deliver 'one-two punch'" captures this dynamic: strong current performance undermined by forward-looking concern. The stock had actually gained 6.3% earlier in July on positive Alzheimer's pipeline data, but that upside momentum appears to have reversed sharply when management's cautious guidance signaled slowing growth ahead. This suggests investors were pricing in continued acceleration rather than the slowdown now being forecast.

TGE.WT

The Generation Essentials Group

$0.13−$0.05

-27.8%

NYSE

No news headlines were found in the last 48 hours for TGE.WT, so the 27.78% drop cannot be attributed to a specific announced event; the decline is likely driven by technical selling, broader market weakness, or an untracked rumor.

The absence of any recent news headlines in the Yahoo Finance RSS feed means we cannot point to a specific catalyst like earnings, a corporate action, product announcement, or regulatory development. For a penny stock warrant trading at $0.13, several common driver categories are plausible: technical stops or liquidations in thinly traded securities can trigger sharp single-day drops; broad equity market weakness on the snapshot date could have rippled into smaller-cap stocks; warrant-specific factors such as deterioration in the underlying equity or changes in implied volatility could compress warrant value even without company-specific news; or an unannounced rumor or insider trading activity could have preceded the decline but not yet appeared in major news feeds. Without access to intraday tape, social media chatter, or insider filings, we cannot distinguish among these possibilities.

CHARR

Charlton Aria Acquisition Corporation Rights

$0.08−$0.03

-26.7%

NASDAQ

No news emerged in the last 48 hours, but CHARR is a SPAC rights offering that likely fell due to market-wide SPAC rotation or deterioration in sentiment toward blank-check acquisition vehicles.

No headlines appeared in the last 48 hours to explain the 26.73% drop. CHARR is structured as a rights offering tied to a SPAC, a security category that has faced persistent headwinds since 2021 as investors reassessed the risk-return profile of blank-check mergers and appetite for pre-deal SPAC equity dried up. Rights offerings typically trade on the credibility of the target deal and the management team; any perceived weakness in deal certainty, valuation, or broader SPAC sentiment can trigger sharp repricing. The stock's low absolute price and rank as the 15th biggest loser suggests sector-wide pressure rather than an isolated firm event, though we cannot confirm which specific catalyst drove this move without additional reporting.

SEGG

Lottery.com, Inc.Consumer Cyclical

$0.42−$0.15

-26.4%

NASDAQ · Mkt cap $8.4 M

No news headlines were published in the last 48 hours about SEGG, so the 26.45% decline cannot be directly attributed to any reported catalyst. The drop likely reflects technical selling, broader market weakness, or unannounced company developments.

The absence of recent news headlines makes it impossible to identify a specific news-driven cause for the sharp 26.45% decline in SEGG stock. Lottery.com is a micro-cap lottery ticket reseller that trades with significant volatility typical of penny stocks and low-liquidity securities. Declines of this magnitude in such stocks can result from several categories of catalyst: technical breakdown after a period of strength, margin calls or forced liquidations by retail traders, delayed disclosure of negative developments, unfounded rumors circulating on social media, or simply the ephemeral nature of speculative interest in micro-cap equities. Without access to news, social media chatter, or intraday trading data, attributing the move to a specific event would be speculation. The timing and magnitude suggest an event occurred, but the evidence does not establish what it was.

HCTI

Hybrid Coating Technologies, Inc.Healthcare

$1.15−$0.41

-26.4%

NASDAQ · Mkt cap $14 M

Healthcare Triangle announced share issuances and a non-binding LOI to acquire a stake in CosmoInnovations on July 29, likely triggering shareholder dilution concerns that drove the stock down 26.37% the following day.

The company released three material announcements on July 29: completion of share issuances tied to legacy M&A deals, a research note flagging the share issuance as positive for long-term strategy, and a non-binding LOI to acquire 51% of CosmoInnovations. While the research note offered a bullish framing, the fact of significant share dilution—especially coupled with entry into a new MedTech market via acquisition—appears to have triggered immediate negative sentiment. The stock dropped 26% the next trading day, suggesting the market interpreted dilution risk and execution uncertainty as outweighing the growth potential highlighted in the analyst commentary. The non-binding nature of the CosmoInnovations deal adds uncertainty about capital requirements and deal terms.

MBRX

Moleculin Biotech IncHealthcare

$1.01−$0.35

-25.5%

NASDAQ · Mkt cap $4.3 M

No news headlines were found in the last 48 hours to explain the 25.46% drop in MBRX stock, suggesting the decline may have been driven by a delayed announcement, technical selling, or market-specific factors not captured in the available news feed.

The absence of any Yahoo Finance headlines in the past 48 hours is notable given the magnitude of the move, which ranks MBRX as the 18th biggest loser of the day on NASDAQ. For a small-cap biotech stock like Moleculin Biotech, the most common catalysts for sharp declines include clinical trial data releases or failures, regulatory setbacks, dilutive financing announcements, changes in cash burn outlook, or insider trading disclosures. Since no news is reflected in the provided headlines, the catalyst could be a late-breaking announcement that hasn't yet propagated to the RSS feed, technical selling pressure, options expiration mechanics, or private information that triggered institutional or insider selling. Without access to real-time company announcements or alternative news sources, the specific driver remains unknown.

LEXX

Lexaria Bioscience Corp.Healthcare

$0.40−$0.13

-24.3%

NASDAQ · Mkt cap $19 M

Lexaria announced a reverse stock split effective today, which typically triggers a sharp one-day decline as investors digest the dilution signal and structural change; the 24% drop is consistent with negative market sentiment around such announcements.

The headline confirms that Lexaria announced an effective date for a reverse stock split on July 30, 2026—the exact date of the observed 24% price decline. Reverse stock splits are commonly perceived negatively by the market because they are often associated with companies attempting to restore compliance with exchange listing standards, signal financial distress, or are viewed as a dilutive restructuring. While the headline does not provide the split ratio, timing, or explicit reason for the reverse split, the announcement alone is sufficient to explain why the stock fell sharply on the day it became effective. Investors selling on the news is a standard market response to reverse split announcements, independent of the company's underlying fundamentals.

KWM

K Wave Media, Ltd.Communication Services

$0.08−$0.03

-24.3%

NASDAQ · Mkt cap $114 M

K Wave Media announced a 1-for-30 reverse stock split effective today, which typically signals financial distress and often triggers sharp selling as investors flee ahead of the consolidation.

A reverse stock split is a structural corporate action in which the company reduces the number of outstanding shares while increasing the price per share proportionally. While mathematically neutral in isolation, reverse splits are widely interpreted by the market as a negative signal, typically indicating the company is struggling to maintain minimum listing standards or is in financial distress. The 24.25% single-day drop on the announcement is consistent with this interpretation. Investors often sell ahead of reverse splits due to historical correlation with further deterioration, dilution risk, or delisting concerns. The timing of the announcement on July 30 at market close (15:30 UTC) suggests the stock traded down on this news during the session. Without additional context on the company's financial condition, runway, or stated reason for the split, the market reaction appears to reflect standard negative sentiment toward this corporate action rather than a new fundamental development.

Regional Management CorpFinancial Services

$32.25−$10.24

-24.1%

NYSE · Mkt cap $309 M

Regional Management Corp reported lower-than-expected guidance for the full year due to competitive pressures and proactive tightening of underwriting standards, which triggered the 24% stock decline despite modest Q2 earnings and revenue growth.

Regional Management released Q2 2026 earnings on July 29-30 showing net income of $0.85 per diluted share with 7% revenue growth to $168 million. However, the company significantly revised full-year guidance downward, citing competitive pressures in the consumer finance market and management's decision to tighten underwriting criteria proactively. The earnings also noted higher credit-loss provisions, which signals deteriorating credit quality or rising default expectations. For a consumer finance company, downward guidance combined with rising loan-loss provisions and tightened underwriting typically signals management concern about economic headwinds or portfolio deterioration ahead. Investors appear to have interpreted the guidance cut and cautious credit outlook as more material than the modest Q2 operational results, driving the sharp selloff.

NMPAR

NMP Acquisition Corp. Right

$0.15−$0.05

-24.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 24% drop in NMPAR rights cannot be traced to a specific catalyst. The decline likely reflects either technical weakness in blank-check acquisition vehicles or a broader shift in sentiment toward SPAC-related securities.

NMPAR is a right issued by a SPAC (special purpose acquisition company) that trades independently of its underlying warrant or common stock. Rights in SPACs are among the most illiquid and volatile instruments in equity markets, often exhibiting sharp moves on minimal volume or sentiment shifts unrelated to fundamental news. Without any news headline provided, the 24% one-day drop could stem from several categories: a broad pullback in SPAC valuations, liquidation or rebalancing by a holder with a large position, technical breakdown in a thinly traded instrument, or delayed announcement of merger terms that market participants were already pricing in. Rights specifically are prone to decay and repricing as redemptions occur and merger deadlines approach. The absence of news does not rule out a known event in the market that simply did not trigger a headline update.

LEGO.WT

$0.38−$0.12

-24.0%

SDST

Stardust Power Inc.Industrials

$0.74−$0.23

-23.7%

NASDAQ · Mkt cap $8.6 M

No news headlines were found in the last 48 hours, so the 23.67% drop cannot be directly attributed to any reported event. The decline likely stems from technical selling, a delayed market reaction, or an undisclosed company announcement.

The absence of any news in the Yahoo Finance RSS feed over the past two days means we cannot point to a specific catalyst such as earnings, guidance changes, regulatory actions, or business developments. For a micro-cap stock like Stardust Power trading at $0.74, sharp single-day declines are not uncommon and can result from several sources: technical selling triggered by a breakdown of support levels, short-seller activity or negative rumors on social media platforms that may not yet appear in major news feeds, a delayed market reaction to an announcement made outside the standard news cycle, insider trading activity that precedes public disclosure, or sector-wide rotation out of speculative energy or renewable power plays. Without confirmed headlines, we cannot distinguish between these possibilities.

INDP

Indaptus Therapeutics, Inc.Healthcare

$1.42−$0.44

-23.7%

NASDAQ · Mkt cap $125 M

No news headlines were found in the last 48 hours, so the 23.66% drop cannot be directly attributed to a specific announced event. The decline is likely driven by technical selling, sector weakness, or undisclosed market rumors affecting this small-cap biotech stock.

Indaptus Therapeutics is a small-cap biopharmaceutical company, and the absence of any news in the last 48 hours despite a substantial single-day decline suggests the move was not triggered by a company-specific announcement or earnings release. For stocks of this type and capitalization, large single-day declines without corresponding news often reflect one of several patterns: momentum-driven technical selling, broad sector rotation out of speculative biotech names, reaction to delayed or missed clinical trial expectations that may not have reached major news wires, short-covering reversal, or increased short-seller activity. Without headline confirmation, attribution is speculative. The stock's small float and low price point make it susceptible to volatility from modest order flow imbalances or thematic shifts in risk appetite toward micro-cap therapeutics.

PHAT

Phathom Pharmaceuticals IncHealthcare

$9.02−$2.62

-22.5%

NASDAQ · Mkt cap $626 M

Phathom reported strong Q2 earnings with 88% revenue growth and first-time positive operating profit, but market sold off 22.51% on the same day, likely driven by physician friction in prior authorization for its lead drug Voquezna or unmet forward guidance expectations.

The earnings headlines present a paradox: Phathom delivered concrete financial wins including record $74.3 million Q2 revenue, 88% year-over-year growth, 33% expense reduction, and achieved profitability excluding stock-based compensation for the first time. Yet the stock fell sharply. The most substantive clue in the headlines is the repeated mention of physician friction surrounding prior authorization for Voquezna, the company's primary revenue driver. This operational headwind could indicate slower future prescription growth despite current momentum. Alternatively, the sell-off may reflect unmet guidance for future quarters, revised market size assumptions, or margin sustainability concerns that emerged during the earnings call but were not detailed in these headline snippets. Without access to the full call transcript or forward guidance provided, the exact trigger remains partially obscured.

AMIX

Autonomix Medical, Inc. Common StockHealthcare

$3.55−$1.02

-22.2%

NASDAQ · Mkt cap $5.7 M

No news headlines were found in the past 48 hours, so the 22% drop likely stems from a clinical setback, regulatory decision, or market rumor specific to Autonomix Medical that has not yet been publicly reported.

Autonomix Medical is a medical device company, and a 22% single-day drop of this magnitude without accompanying headlines in the major news feed suggests either a material announcement that has not yet propagated to Yahoo Finance's RSS feed, or a significant adverse development known to insiders or the market. Possible categories include negative clinical trial results, an FDA rejection or warning letter, unexpected cash burn or financing concerns, or loss of a key partnership. Medical device companies are particularly sensitive to regulatory and clinical outcomes. Without confirmed headlines, however, we cannot pinpoint the specific trigger. It is also possible that a press release was issued outside regular market hours or that social media or company sources disclosed information before major news wires picked it up.

LVWR

Livewire Group IncConsumer Cyclical

$2.14−$0.56

-21.6%

NYSE · Mkt cap $254 M

LiveWire Group received a NYSE deficiency letter on July 23 regarding trading share price listing rule non-compliance, triggering a 21.6% single-day drop as the market priced in delisting risk.

The headline confirms that LiveWire received a formal notice from the NYSE on July 23, 2026, citing non-compliance with trading share price listing rules. This is a material regulatory event that typically signals the company has breached minimum share price thresholds or related listing standards. Such deficiency letters are precursors to potential delisting if the company cannot cure the violation within a specified cure period, usually 90 days to six months depending on the rule. The market's sharp 21.6% sell-off on July 30 is a direct rational response to this disclosed regulatory jeopardy. Investors likely reassess the equity's value when delisting becomes a tangible risk, as it reduces liquidity, analyst coverage, and institutional eligibility for holding, creating a negative feedback loop. The headline provides sufficient specificity about the event, though the notice itself was issued on July 23, with the market reaction appearing on July 30, a typical lag for full price discovery.

RDCM

RADCOM LtdCommunication Services

$10.02−$2.70

-21.2%

NASDAQ · Mkt cap $173 M

RADCOM announced preliminary Q2 revenue and updated full-year 2026 guidance on July 30, likely disappointing investor expectations and triggering the 21% sell-off ahead of the formal August 12 earnings release.

The company released preliminary second quarter revenue and revised its full-year outlook, which appears to have prompted a sharp market reaction. While the headline does not explicitly state whether guidance was raised, lowered, or merely maintained, the magnitude of the decline—RDCM ranking as the 29th biggest loser on the day—suggests the preliminary numbers or updated forecast fell short of market expectations. For small-cap technology and communications software vendors like RADCOM, guidance misses or revenue shortfalls commonly trigger sharp repricing, especially when announced ahead of a formal earnings call. The timing of the preliminary disclosure may also have created selling pressure from those who viewed the pre-announcement as a signal of weakness.

LBGJ

LBGJIndustrials

$0.02−$0.00

-20.3%

NASDAQ · Mkt cap $58 K

Li Bang International announced a 1-for-200 share consolidation, which typically triggers sharp stock price declines on the announcement day as market participants digest the dilutive mechanics and signal of financial distress common to reverse splits.

The company announced a 1-for-200 share consolidation on July 29, 2026. While the headline was truncated and did not provide full details on rationale or timing, share consolidations of this magnitude are almost universally market-negative events. They are typically used by distressed companies to regain compliance with minimum share price requirements or as a restructuring tool when the stock has deteriorated significantly. The 20.34% single-day drop aligns with historical patterns for reverse split announcements, where shareholders immediately mark down the stock due to concern about dilution in the capital structure, reduced liquidity post-consolidation, or the underlying signal that management views the stock price as unsustainably low. The fact that LBGJ trades at $0.02 suggests it was already in severe distress before the announcement, making the consolidation a last-resort measure. Without the full press release text, we cannot determine whether management provided forward guidance or additional context that might soften or amplify the sell-off.

ZIVO

Zivo Bioscience, Inc.Healthcare

$4.00−$1.00

-20.0%

NASDAQ · Mkt cap $17 M

No news headlines were found in the last 48 hours to explain ZIVO's 20% drop, so the cause remains unclear without additional context about the biotech firm's operations or market conditions.

The absence of any recent news headlines is notable given ZIVO's sharp 20% decline, ranking it among the day's worst performers. For a small-cap biotech stock like Zivo Bioscience, catalysts typically include clinical trial results, FDA decisions, financing announcements, or management changes. Without access to headlines, the move could reflect several possibilities: a delayed negative announcement not yet picked up by major news feeds, technical selling or profit-taking, sector-wide biotech weakness, insider trading activity, or reaction to an earnings report or conference call. The lack of reported news does not rule out any of these scenarios. Without specific information about ZIVO's current pipeline, financial position, or recent corporate events, attributing the move to a particular cause would be speculation.

TREE

LendingTree IncFinancial Services

$31.81−$7.61

-19.3%

NASDAQ · Mkt cap $440 M

LendingTree missed Q2 revenue estimates and lowered its 2026 outlook due to higher costs and weakness in consumer lending, triggering a 19.3% sell-off as investors repriced growth expectations downward.

LendingTree reported Q2 2026 earnings on July 29-30 that fell short of Wall Street expectations. While the company posted 25.3% year-over-year revenue growth to $313.4 million, this still missed analyst estimates. More critically, management cited higher costs pressuring margins and persistent weakness in small-business lending within the consumer segment. The company then lowered its full-year 2026 guidance, with Q3 revenue guidance of $330 million coming in below expectations. The earnings call revealed that while insurance revenue showed strong momentum and the firm is investing in AI expansion, these bright spots were insufficient to offset the disappointing near-term trajectory. Lower guidance typically triggers significant repricing, especially when combined with margin pressures and segment-specific headwinds, explaining the sharp 19.3% decline that made TREE the 32nd biggest loser on the day.

NCRA

Nocera Inc.Consumer Defensive

$2.37−$0.52

-18.8%

NASDAQ · Mkt cap $3.2 M

Nocera announced three positive corporate developments on July 29—Nasdaq compliance restoration, binding transactions, and a QMAX Technology acquisition—yet the stock fell 18.84% the following day, suggesting investor disappointment with deal terms, valuation concerns, or unrelated market pressur…

The news released on July 29 was substantively positive: regaining Nasdaq compliance after a delisting threat, securing three binding transactions within sixty days, and acquiring QMAX Technology to access Micron memory distribution channels and strengthen AI infrastructure positioning. These announcements typically support stock price recovery. However, the stock dropped sharply on July 30, the day after these releases. This disconnect suggests either that investors found the deal terms, acquisition pricing, or capital structure unfavorable upon closer analysis, or that negative information not captured in these headlines (financing dilution, insider selling, analyst downgrades) emerged during or after market hours on July 29. Without access to deal valuation metrics, share count impact, or market commentary, the precise reason for the sell-off cannot be determined from the provided news alone.

AFJKR

Aimei Health Technology Co., Ltd Right

$0.09−$0.02

-18.1%

NASDAQ

No news headlines were found in the last 48 hours to explain the 18% drop, so the cause remains unclear; possible drivers include technical selling, delayed news, or sector rotation in microcap stocks.

The absence of any news headlines in the last 48 hours makes it difficult to pinpoint a specific catalyst for the 18.09% decline in AFJKR. This is a rights offering security tied to Aimei Health Technology, a microcap healthcare stock on NASDAQ. Microcap and sub-dollar stocks are particularly sensitive to technical factors such as stop-loss cascades, short-covering reversals, or margin calls, and can move sharply on low volume without requiring news. A second possibility is that a material announcement (earnings, clinical results, regulatory news, or insider selling) occurred but has not yet been picked up by major financial news feeds. Alternatively, this could reflect broader sector weakness in healthcare or biotech stocks, or a delayed market reaction to older news not captured in the 48-hour window. Without headline confirmation, attribution remains speculative.

KPET.WT

KPET Ultra Paceline Corporation WT

$0.50−$0.11

-18.0%

HODO

House of Doge Inc.Technology

$0.64−$0.14

-17.6%

NASDAQ · Mkt cap $33 M

No news headlines were found in the last 48 hours to explain the 17.57% drop in HODO stock. The decline likely reflects either technical selling pressure, delayed market reaction to an untracked announcement, or sentiment shift among retail/speculative traders in this micro-cap name.

Yahoo Finance returned zero headlines for HODO in the last 48 hours despite the stock ranking as the 36th biggest loser of the day, which is a red flag that either the catalyst is not being widely covered by mainstream news feeds, or the move is driven by non-news factors. Stocks trading at $0.64 (micro-cap territory) are often subject to volatility from thin liquidity, retail trading dynamics, or short-squeeze reversals rather than fundamental catalysts. Without access to alternative news sources, SEC filings, or real-time social sentiment data, it is impossible to pinpoint whether this was sparked by company-specific guidance, insider selling, sector rotation, or purely technical de-leveraging. The absence of news coverage itself suggests the move may not be tied to a major corporate announcement.

APUS

Apimeds Pharmaceuticals US, IncHealthcare

$4.74−$1.01

-17.6%

SXTP

60 Degrees Pharmaceuticals, Inc. - Common StockHealthcare

$1.25−$0.26

-17.5%

NASDAQ · Mkt cap $3.1 M

60 Degrees Pharmaceuticals fell 17.46% following announcement of a private placement at-the-market offering on July 30, which typically causes dilution and suggests the company needed to raise capital urgently.

The company announced a private placement priced at-the-market under Nasdaq rules on the same day as the stock's largest decline, making this the most direct candidate for the drop. At-the-market offerings represent equity dilution to existing shareholders and often signal capital needs that cannot be met through other means. The positive news from July 29 regarding minimum enrollment achievement in the babesiosis study and an interim readout planned by October 6 would normally be viewed as catalytic for a clinical-stage biotech, but the dilutive capital raise announcement the next day appears to have overwhelmed that sentiment. The timing of the offering announcement after market hours on the same day suggests the market may have been surprised by the need for immediate funding despite the clinical milestone, or the offering was larger than expected relative to the stock price.

SONO

Sonos IncTechnology

$14.49−$3.04

-17.3%

NASDAQ · Mkt cap $1.9 B

Sonos reported strong Q3 earnings with revenue and profit beats, but the stock fell 17% likely due to significant memory cost pressures and a weakened Q4 outlook that overshadowed the positive results.

The headlines confirm that Sonos delivered a genuine earnings beat on July 29, with revenue of $375 million (9% growth), net income improvement, and adjusted EBITDA beating guidance by 24%. The company also completed a $115 million share buyback, which is typically positive. However, the earnings call highlights explicitly mention significant memory cost pressures that are impacting Q4 outlook. This forward guidance concern appears to have overwhelmed the beat itself. The initial market reaction on July 30 morning showed the stock up 20.6%, suggesting initial optimism about the earnings surprise. The 17% intraday reversal suggests that as the market digested the full earnings call and the severity of anticipated Q4 headwinds, investors repriced the stock downward. The cost pressure commentary likely signals lower margins ahead, offsetting the current-quarter strength and making future earnings growth questionable.

IAUX.WT

i-80 Gold Corp. WT

$0.60−$0.12

-17.2%

FICO

Fair Isaac CorpTechnology

$1,139.54−$236.59

-17.2%

NYSE · Mkt cap $21 B

FICO dropped 17% despite beating Q3 earnings and raising full-year guidance, likely because the company issued lower-than-expected forward guidance that spooked investors despite strong current-quarter results.

The headlines present a contradiction that explains the sharp sell-off. FICO reported a standout third quarter with 26% revenue growth, 42% non-GAAP EPS growth, and a raised fiscal 2026 outlook, all of which beat estimates. However, the most recent headline explicitly states the stock dropped after the company issued lower-than-expected guidance. This is a classic earnings whipsaw: initial positive beats on current results were overwhelmed by disappointment in forward guidance. Investors rewarded the strong quarter during after-hours trading, but when management's forward outlook proved softer than Wall Street anticipated, selling pressure intensified, resulting in the largest daily drop in six years. The exact nature of the missed guidance is not detailed in the headlines provided, but the pattern is clear: future growth expectations reset lower.

WETO

Webus International Limited Ordinary SharesTechnology

$0.03−$0.01

-17.1%

NASDAQ · Mkt cap $11 M

Wetour Robotics announced a share consolidation on July 29, which typically signals financial distress and dilution concerns, likely driving the 17% single-day drop as investors reassess the stock's trajectory.

The headline confirms that Wetour Robotics Limited announced a share consolidation effective July 29, 2026. Share consolidations are corporate actions where multiple existing shares are combined into fewer shares at a higher nominal price per share. While the full details are not provided in the truncated headline, such announcements often reflect efforts to maintain minimum listing standards or improve optics around a depressed stock price. Investors typically view consolidations negatively because they do not create economic value and often precede further dilution or signal management's concern about the stock's trading profile. The timing of the announcement and the sharp 17% decline the same trading day suggests market participants immediately repriced the stock upon learning of this structural change. Without additional context on the consolidation ratio or accompanying guidance, the precise mechanic cannot be fully determined, but the negative reaction is consistent with historical market responses to such announcements in microcap stocks.

GPI

Group 1 Automotive IncConsumer Cyclical

$296.68−$60.16

-16.9%

NYSE · Mkt cap $3.4 B

Group 1 Automotive reported Q2 earnings and revenue that missed Wall Street estimates, with weaker consumer affordability pressuring vehicle sales and profitability, directly triggering the 16.86% sell-off.

The stock's sharp decline on July 30 aligns directly with the release of Group 1's second-quarter 2026 financial results. Multiple headlines confirm the company missed both earnings and revenue estimates, with earnings down 10.94% and revenue down 4.69% versus expectations. The stated driver was softening consumer spending and weaker affordability for vehicle purchases, which pressured both sales volume and margins. The company did announce an acquisition of Hennessy Automobile Dealerships in Atlanta on the same day, but that positive move appears overshadowed by the earnings disappointment. The magnitude of the decline reflects investor disappointment in both current-quarter performance and likely downward revisions to forward guidance given the consumer spending headwinds cited.

CUPR

Cuprina Holdings (Cayman) Limited Class A Ordinary SharesHealthcare

$2.50−$0.54

-16.8%

NASDAQ · Mkt cap $8.0 M

No news headlines appeared in the last 48 hours for CUPR, so the 16.82% drop likely reflects either a delayed market reaction to an earlier announcement, technical selling, or a company-specific event that has not yet been widely reported.

The absence of recent news headlines makes it impossible to identify a specific catalyst from the provided information. CUPR is a small-cap Cayman Islands-incorporated holding company trading on NASDAQ, and such companies can experience sharp moves on limited volume, technical factors, or news that has not yet propagated through major financial RSS feeds. The stock could have reacted to an announcement made before the 48-hour window, insider transactions, analyst downgrades not captured here, sector rotation, or micro-cap volatility unrelated to fundamentals. Without access to company filings, press releases, or trading data, assigning a specific cause would be speculative.

DCX

Chijet Motor Company, Inc.Consumer Cyclical

$1.24−$0.24

-16.8%

NASDAQ · Mkt cap $322 M

No news headlines were found in the last 48 hours, so the 16.78% decline in DCX cannot be directly attributed to a specific announced event; the drop likely reflects broader market sentiment, technical selling, or unannounced company developments.

The absence of any recent news headlines makes it difficult to pinpoint a concrete catalyst for the sharp 16.78% decline in DCX stock. Chijet Motor Company is a smaller-cap NASDAQ-listed entity, and stocks in this category can experience significant intraday volatility driven by factors other than breaking news, including technical chart breaks, options expiration activity, short covering reversals, or delayed disclosure of internal developments not yet picked up by major news feeds. Without access to real-time trading data, analyst downgrades, social media sentiment, or insider transactions, the most likely explanations remain speculative. The move is substantial enough to suggest more than random noise, but confirmation of the underlying cause would require either delayed news publication or access to alternative data sources beyond the provided 48-hour window.

KRSP.WT

$1.02−$0.21

-16.7%

LTCH

Latch, Inc.Technology

$0.15−$0.03

-16.4%

NASDAQ · Mkt cap $31 M

No news was reported in the last 48 hours, so the 16.43% drop cannot be attributed to a specific announced event; the decline likely reflects either technical selling pressure, broader market conditions, or unreported developments.

The absence of any recent headlines makes it impossible to pinpoint a concrete catalyst for Latch's sharp decline today. Latch is a small-cap fintech and smart building access company historically subject to significant volatility, especially given its penny-stock trading range near $0.15. The drop could stem from several generic categories: technical selling pressure following a prior rally, broader market weakness in growth or fintech sectors, investor sentiment shifts regarding the company's path to profitability, or unannounced company developments that may emerge later through SEC filings or press releases outside the captured news feed. Without headline evidence or knowledge of recent company-specific structural catalysts, the specific trigger remains unknown and must be investigated through direct SEC filings or company communications.

NUWE

Nuwellis, Inc.Healthcare

$4.48−$0.58

-16.2%

NASDAQ · Mkt cap $3.7 M

Nuwellis announced peer-reviewed research supporting an alternative anticoagulation strategy for its Aquadex device on July 30, but the stock fell 16.17% the same day, suggesting the market either viewed the findings as incremental, faced headwinds unrelated to this news, or reacted to broader se…

The single headline provided is positive in nature—acceptance of a pediatric study in a peer-reviewed journal demonstrating that an alternative anticoagulation approach (epoprostenol) maintained circuit performance without observed bleeding complications. This is typically the kind of clinical validation that supports market sentiment. However, the stock dropped sharply the same day the news was released. This disconnect suggests either the market had already priced in expectations for stronger clinical data, the clinical findings were seen as too narrow in applicability (single-center, retrospective, pediatric-only), or the selling pressure came from unrelated factors such as sector headwinds, short liquidation, or undisclosed company or market developments. Without additional earnings data, guidance changes, or broader context, the precise cause remains unclear.

RBLX

Roblox CorporationCommunication Services

$48.63−$7.71

-15.6%

NYSE · Mkt cap $31 B

Roblox missed second quarter expectations on key metrics and issued weak third quarter bookings guidance below Wall Street estimates, citing engagement headwinds from new age-verification and safety features that are dampening user onboarding.

The headlines establish a clear earnings-driven sell-off triggered by two interconnected misses. First, Roblox reported Q2 results below analyst expectations on unspecified key metrics. Second and more materially, the company issued Q3 bookings guidance well below consensus estimates. The headlines attribute this guidance miss directly to operational challenges: tougher age-verification measures and enhanced safety features are weighing on both new user onboarding and existing user engagement. This represents a classic growth-stock penalty where forward guidance deterioration compounds a quarterly miss. Investors are punishing not just the past quarter but more importantly the trajectory, with safety-driven headwinds suggesting near-term headwinds to core user acquisition and monetization before potential recovery.

CHRW

CH Robinson Worldwide IncIndustrials

$147.06−$26.72

-15.4%

NASDAQ · Mkt cap $17 B

C.H. Robinson beat Q2 earnings and revenue estimates with strong pricing and AI gains, yet the stock fell 15.4%, suggesting the market had already priced in positive results and may be concerned about forward guidance, cash flow weakness, or ongoing job cuts offsetting the earnings beat.

The headlines establish that CHRW delivered a clear earnings beat: EPS surprise of +5.23%, revenue surprise of +11.74%, with sales up 19.3% year-over-year to $4.93 billion. Management highlighted market-share gains, productivity improvements from Lean AI, and margin targets achieved. However, multiple sources note weaker cash flow and ongoing job cuts despite the operating performance. The sell-off on positive earnings suggests either that market expectations were already high enough to price in the beat, or that investors are concerned about forward guidance (not disclosed in these headlines), cash conversion issues, or margin sustainability. The sheer magnitude of the decline on a genuine earnings beat is unusual and points to either guidance disappointment or a broader freight-transportation sector headwind not captured in these snippets.